gsk372475
Small moleculeexperimental
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2001 (NCT00032916)
Timeline
Indications
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
- Norepinephrine transporterINHIBITOR
SC6A2 inhibitor
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk372475
- gsk372475
- gsk372475
- ns2359
- ns2359
- ns2359
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02798627 | Phase 2 | May 1, 2016 | Saniona, The Dana Foundation, University of Pennsylvania |
| NCT00728208 | Phase 1 | Jul 28, 2008 | GlaxoSmithKline |
| NCT00488098 | Phase 1 | Jul 1, 2007 | GlaxoSmithKline |
| NCT00448058 | Phase 2 | Apr 1, 2007 | GlaxoSmithKline |
| NCT00420641 | Phase 2 | Dec 1, 2006 | GlaxoSmithKline |
| NCT00467428 | Phase 2 | Aug 1, 2003 | Harvard University, NeuroSearch A/S |
| NCT00032916 | Phase 1 | Jun 1, 2001 | National Institute on Drug Abuse (NIDA), Uniformed Services University of Health Sciences |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2006 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 1 | 1 | 2001 |
| NeuroSearch A/S | For profit | 1 | 1 | 1 | 2003 |
| Saniona | For profit | 1 | 0 | 1 | 2016 |
| The Dana Foundation | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Uniformed Services University of Health Sciences | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2016 |
8 organizations
Page 1 / 1